Therapeutic potential of N-acetylcysteine in acrylamide acute neurotoxicity in adult zebrafish
Autor/a
Gómez Canela, Cristian
Faria, Melissa
Prats, Eva
Hsu, Chuan-Yu
Arick, Mark A. II
Bedrossiantz, Juliette
Orozco, Manuel
Garcia-Reyero, Natàlia
Ziv, Tamar
Ben-Lulu, Shani
Admon, Arie
Raldúa, Demetrio
Altres autors/es
Universitat Ramon Llull. IQS
Data de publicació
2019-11Resum
Two essential key events in acrylamide (ACR) acute neurotoxicity are the formation of adducts with nucleophilic sulfhydryl groups on cysteine residues of selected proteins in the synaptic terminals and the depletion of the glutathione (GSx) stores in neural tissue. The use of N-acetylcysteine (NAC) has been recently proposed as a potential antidote against ACR neurotoxicity, as this chemical is not only a well-known precursor of the reduced form of glutathione (GSH), but also is an scavenger of soft electrophiles such as ACR. In this study, the suitability of 0.3 and 0.75 mM NAC to protect against the neurotoxic effect of 0.75 mM ACR has been tested in vivo in adult zebrafish. NAC provided only a mild to negligible protection against the changes induced by ACR in the motor function, behavior, transcriptome and proteome. The permeability of NAC to cross blood-brain barrier (BBB) was assessed, as well as the ACR-scavenging activity and the gamma-glutamyl-cysteine ligase (γ-GCL) and acylase I activities. The results show that ACR not only depletes GSx levels but also inhibits it synthesis from NAC/cysteine, having a dramatic effect over the glutathione system. Moreover, results indicate a very low NAC uptake to the brain, probably by a combination of low BBB permeability and high deacylation of NAC during the intestinal absorption. These results strongly suggest that the use of NAC is not indicated in ACR acute neurotoxicity treatment.
Tipus de document
Article
Versió publicada
Llengua
English
Matèries (CDU)
615 - Farmacologia. Terapèutica. Toxicologia. Radiologia
Paraules clau
Neurotoxicologia
Química farmacèutica
Tecnologia farmacèutica
Neurotoxicity syndromes
Pharmacodynamics
Pàgines
11 p.
Publicat per
Nature Research
Publicat a
Scientific Reports. Vol.9, n.1 (2019), 16467
Número de l'acord de la subvenció
info:eu-repo/grantAgreement/NATO/SfP/MD.SFPP 984777
info:eu-repo/grantAgreement/MICINN/PN I+D/CTM2017-83242-R
info:eu-repo/grantAgreement/SUR del DEC/BP/2016 BP 00233
Nota
Al 2020 es publica una correcció a Scientific Reports. Vol.10, n.1 (2020), 2247 (https://doi.org/10.1038/s41598-020-58946-z)
Aquest element apareix en la col·lecció o col·leccions següent(s)
Drets
© L'autor/a
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by/4.0/